BioShield II Patent Provisions Provide Disproportionate Reward To Pharma – Sen. Schumer
This article was originally published in The Pink Sheet Daily
Executive Summary
The wildcard patent rules in BioShield II are a “boondoggle” that put pharma companies’ interests ahead of bioterrorism preparedness, Sen. Schumer (D-N.Y.) maintained in a July 21 roundtable discussion. Bill sponsor Sen. Lieberman (D-Conn.) countered that large incentives are needed to entice companies to develop bioterrorism countermeasures.